MATEVER 100 MG / ML CONCENTRATE FOR SOLUTION FOR INFUSION - patient leaflet, side effects, dosage

Read all of this leaflet carefully before you or your child start using this medicine because it contains important information for you.

• – Keep this leaflet. Y ou may need to read it again.

• – If you have any further questions, ask your doctor or pharmacist.

• – This medicine has been prescribed for you only. Do not pass it on to others. It may harm them,

even if their signs of illness are the same as yours.

• – If you get any side effects, talk to your doctor or pharmacist. This includes any possible side

effects not listed in this leaflet. See section 4.

What is in this leaflet

• 1. What Matever is and what it is used for

• 2. What you need to know before you are given Matever

• 3. How Matever is given

• 4. Possible side effects

• 5. How to store Matever

• 6. Contents of the pack and other information

1. what matever is and what it is used for

Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).

Matever is used:

• on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.
• as an add-on to other antiepileptic medicines to treat:

• ■ partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age

• ■ myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.

• ■ primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Matever concentrate is an alternative for patients when administration of the antiepileptic oral Matever medicine is temporarily not feasible.

2. what you need to know before you are given matever if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this

medicine (listed in Section 6).

Warnings and precautions

Talk to your doctor before you are given Matever

• If you suffer from kidney problems, follow your doctor's instruc­tions. He/she may decide if

your dose should be adjusted.

• If you notice any slowdown in the growth or unexpected puberty development of your child,

please contact your doctor.

• A small number of people being treated with anti-epileptics such as Matever have had thoughts

of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.

• If you have a family or medical history of irregular heart rhythm (visible on an

electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.

Tell your doctor or pharmacist if any of the following side effects gets serious or lasts longer than a few days:

• Abnormal thoughts, feeling irritable or reacting more aggressively than usually or if you or your family and friends notice important changes in mood or behaviour.
• Aggravation of epilepsy

Your seizures may rarely become worse or happen more often, mainly during the first month after the start of the treatment or increase of the dose. If you experience any of these new symptoms while taking Matever, see a doctor as soon as possible.

Children and adolescents

• Matever is not indicated in children and adolescents below 16 years on its own (monotherapy)

Other medicines and Matever

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Do not take macrogol (a medicine used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor.

You should not stop your treatment without discussing this with your doctor.

A risk of birth defects for your unborn child cannot be completely excluded.

Breast-feeding is not recommended during treatment.

Driving and using machines

Matever may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.

Matever contains sodium

This medicine contains 57.21 mg sodium (main component of cooking/table salt) in each maximum single dose. This is equivalent to 2.86 % of the recommended maximum daily dietary intake of sodium for an adult.

3. How Matever is given

Adults (>18 years) and adolescents (12 to 17 years) weighing 50 kg or more:

Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:

General dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day.

Method and route of administration

Matever is for intravenous use. The recommended dose must be diluted in at least 100 ml of a compatible diluent and infused over 15 minutes.

For doctors and nurses, more detailed direction for the proper use of Matever is provided in section 6.

Duration of treatment

• There is no experience with administration of intravenous levetiracetam for a longer period than

• 4 days.

If you stop using Matever

If stopping treatment, as with other antiepileptic medicines, Matever should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Matever treatment, he/she will instruct you about the gradual withdrawal of Matever.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately, or go to your nearest emergency department, if you experience:

• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction
• swelling of the face, lips, tongue and throat (Quincke’s oedema)
• flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])
• symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function
• a skin rash which may form blisters and look like small targets (central dark spots surrounded

by a paler area, with a dark ring around the edge) (erythema multiforme )

• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and

genitals (Stevens-Johnson syndrome )

• a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic

epidermal necrolysis )

• signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.

The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.

• Very common: may affect more than 1 in 10 people nasopharyngitis;
• somnolence (sleepiness), headache.

Common: may affect up to 1 in 10 people

• anorexia (loss of appetite);
• depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
• convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness),

lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);

• vertigo (sensation of rotation);
• cough;
• abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
• rash;
• asthenia/fatigue (tiredness).

Uncommon: may affect up to 1 in 100 people

• decreased number of blood platelets, decreased number of white blood cells;
• weight decrease, weight increase;
• suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, an­ger,

confusion, panic attack, emotional instability/mood swings, agitation;

• amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia

(impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);

• diplopia (double vision), vision blurred;
• elevated/abnormal values in a liver function test;
• hair loss, eczema, pruritus;
• muscle weakness, myalgia (muscle pain);
• injury.

Rare: may affect up to 1 in 1,000 people

• infection;
• decreased number of all blood cell types;
• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction],

Quincke’s oedema [swelling of the face, lips, tongue and throat]);

• decreased blood sodium concentration;
• suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable

to concentrate);

• delirium;
• encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of

symptoms);

• seizures may become worse or happen more often;
• uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);
• change of the heart rhythm (Electrocardi­ogram);
• pancreatitis;
• liver failure, hepatitis;
• sudden decrease in kidney function;
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded

by a paler area, with a dark ring around the edge) (erythema multiforme ), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome ), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis );

• rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.
• limp or difficulty walking.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in By reporting side effects you can help provide more information on the safety of this medicine.

5. how to store matever

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the vial and carton box after “EXP”. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

6. contents of the pack and other informationthe active substance is called levetiracetam. each ml of solution for infusion contains 100 mg of levetiracetam.

The other ingredients are: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections.

What Matever looks like and contents of the pack

Matever concentrate for solution for infusion (Matever concentrate) is a clear, colorless, sterile liquid.

Matever concentrate 5 ml vial is packed in a cardboard box of 10 vials.

Marketing Authorisation Holder and Manufacturer

Pharmathen S.A.

6, Dervenakion str.

15351 Pallini, Attiki

Greece

This leaflet was last revised in

The following information is intended for healthcare professionals only:

Directions for the proper use of Matever is provided in section 3.

One vial of Matever concentrate contains 500 mg levetiracetam (5 ml concentrate of 100 mg/ml). See Table 1 for the recommended preparation and administration of Matever concentrate to achieve a total daily dose of 500 mg, 1000 mg, 2000 mg, or 3000 mg in two divided doses.

Table 1. Preparation and administration of Matever concentrate

This medicine is for single use only any unused solution should be discarded.

In use shelf life: from a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage time and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

Matever concentrate was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 1525°C.

Diluents:

• Sodium chloride (0.9 %) inj ection
• Lactated Ringer's injection
• Dextrose 5 % injection